{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:01:51Z","timestamp":1789225311786,"version":"build-2803163510"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[1998,5,1]],"date-time":"1998-05-01T00:00:00Z","timestamp":893980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1998,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            In this multicenter study, the efficacy of and tolerability for meropenem were compared with those for the combination of cefuroxime-gentamicin (\u00b1metronidazole) for the treatment of serious bacterial infections in patients \u226565 years of age. A total of 79 patients were randomized; thirty-nine received meropenem (1 g\/8 h), and 40 received cefuroxime (1.5 g\/8 h) plus gentamicin (4 mg\/kg of body weight daily) for 5 to 10 days. Metronidazole (500 mg\/6 h) could be added to the cefuroxime-gentamicin regimen for the treatment of intra-abdominal infections (\n            <jats:italic>n<\/jats:italic>\n            = 10). Seventy patients were evaluable for clinical efficacy; the primary diagnoses were as follows: pneumonia in 41 patients (20 treated with meropenem, 21 treated with cefuroxime-gentamicin), intra-abdominal infection in 10 patients (7 meropenem, 3 cefuroxime-gentamicin-metronidazole), urinary tract infection (UTI) in 11 patients (6 meropenem, 5 cefuroxime-gentamicin), sepsis syndrome in 7 patients (4 meropenem, 3 cefuroxime-gentamicin), and \u201cother\u201d in 1 patient (cefuroxime-gentamicin). The pathogens isolated from 18 patients with bacteremia were as follows:\n            <jats:italic>Staphylococcus<\/jats:italic>\n            spp. (\n            <jats:italic>n<\/jats:italic>\n            = 2),\n            <jats:italic>Streptococcus<\/jats:italic>\n            spp. (\n            <jats:italic>n<\/jats:italic>\n            = 2), members of the family\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            (\n            <jats:italic>n<\/jats:italic>\n            = 11), and\n            <jats:italic>Bacteroides<\/jats:italic>\n            spp. (\n            <jats:italic>n<\/jats:italic>\n            = 3). A satisfactory clinical response at the end of therapy was achieved in 26 of 37 (70%) and 24 of 33 (73%) evaluable patients treated with meropenem and combination therapy, respectively. Clinical success was achieved in 23 of 31 (74%) and 21 of 28 (75%) evaluable patients with infections other than UTIs, respectively. A satisfactory microbiological response occurred in 15 of 22 (68%) patients in the meropenem group compared with 12 of 19 (63%) treated with combination therapy. Renal failure occurred during therapy in 2 of 39 (5%) meropenem recipients compared with 5 of 40 (13%) of those treated with combination therapy. The findings in this small study indicate that meropenem is as efficacious for and as well tolerated by elderly patients as the combination of cefuroxime-gentamicin (\u00b1metronidazole).\n          <\/jats:p>","DOI":"10.1128\/aac.42.5.1233","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:31:56Z","timestamp":1539045116000},"page":"1233-1238","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":25,"title":["Meropenem versus Cefuroxime plus Gentamicin for Treatment of Serious Infections in Elderly Patients"],"prefix":"10.1128","volume":"42","author":[{"given":"C. A. J. J.","family":"Jaspers","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Department of Medicine, Division of Infectious Diseases and AIDS,1 and"},{"name":"<!--label omitted: 2-->Department of Medicine, Central Military Hospital,2 Utrecht,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kieft","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Department of Intensive Care,3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Speelberg","sequence":"additional","affiliation":[{"name":"<!--label omitted: 4-->Department of Intensive Care,4 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Buiting","sequence":"additional","affiliation":[{"name":"<!--label omitted: 5-->Department of Microbiology,5 St. Elisabeth Hospital, Tilburg,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"van Marwijk Kooij","sequence":"additional","affiliation":[{"name":"<!--label omitted: 6-->Department of Medicine,6 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J. H. M.","family":"Ruys","sequence":"additional","affiliation":[{"name":"<!--label omitted: 7-->Department of Microbiology,7 Sophia Hospital, Zwolle,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. H.","family":"Vincent","sequence":"additional","affiliation":[{"name":"<!--label omitted: 8-->Department of Medicine, St. Antonius Hospital, Nieuwegein,8 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C. A.","family":"Vermeulen","sequence":"additional","affiliation":[{"name":"<!--label omitted: 9-->Department of Medicine, Elkerliek Hospital, Helmond,9 The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Olink","sequence":"additional","affiliation":[{"name":"<!--label omitted: 10-->Kendle\/U-gene Research,10and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. M.","family":"Hoepelman","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Medicine, Division of Infectious Diseases and AIDS,1 and"},{"name":"<!--label omitted: 11-->Eijkman-Winkler Institute,11University Hospital Utrecht and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/bmj.312.7027.338","article-title":"Single or multiple daily doses of aminoglycosides: a meta-analysis.","volume":"312","author":"Barza M.","year":"1996","unstructured":"Barza M. Ioannidis J. P. A. Cappelleri J. C. Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 312 1996 338 345","journal-title":"BMJ"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Bax R. P. W. Bastain A. Featherstone D. M. Wilkinson M. Hutchison and S. J. Haworth. 1989. The pharmacokinetics of meropenem in volunteers. J. Antimicrob. Chemother. 24 (Suppl. A) : 311\u2013320.","DOI":"10.1093\/jac\/24.suppl_A.311"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/clind\/15.Supplement_1.S5","article-title":"General guidelines for the clinical evaluation of anti-infective drug products.","volume":"15","author":"Beam T. R.","year":"1992","unstructured":"Beam T. R. Gilbert D. N. Kunin C. M. General guidelines for the clinical evaluation of anti-infective drug products. Clin. Infect. Dis. 15 1992 S5 S31","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00019053-199201060-00005","article-title":"Imipenem\/cilastatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections.","volume":"1","author":"Benfield P.","year":"1992","unstructured":"Benfield P. Chrisp P. Imipenem\/cilastatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections. Pharmacoeconomics 1 1992 443 449","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00003246-198905000-00002","article-title":"Sepsis syndrome: a valid clinical entity.","volume":"17","author":"Bone R. C.","year":"1989","unstructured":"Bone R. C. Fisher C. J. Clemmer J. P. Slotman G. J. Metz C. A. Blak R. A. Sepsis syndrome: a valid clinical entity. Crit. Care Med. 17 1989 389 393","journal-title":"Crit. Care Med."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/clinids\/21.3.544","article-title":"Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial.","volume":"21","author":"Condon R. E.","year":"1995","unstructured":"Condon R. E. Walker A. P. Sirinek K. R. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin. Infect. Dis. 21 1995 544 550","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.1.86"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/clinids\/22.2.209","article-title":"Infections in the elderly.","volume":"22","author":"Crossley K. B.","year":"1996","unstructured":"Crossley K. B. Peterson P. K. Infections in the elderly. Clin. Infect. Dis. 22 1996 209 215","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_10_2","first-page":"5","article-title":"Laboratory data which differentiate meropenem and imipenem.","volume":"96","author":"Edwards J. R.","year":"1995","unstructured":"Edwards J. R. Turner P. J. Laboratory data which differentiate meropenem and imipenem. Scand. J. Infect. Dis. Suppl. 96 1995 5 10","journal-title":"Scand. J. Infect. Dis. Suppl."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0196-6553(88)90053-3"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Geroulanos S. J. and the Meropenem Study Group. 1995. Meropenem versus imipenem\/cilastatin in intra-abdominal infections requiring surgery. J. Antimicrob. Chemother. 36 (Suppl. A) : 191\u2013205.","DOI":"10.1093\/jac\/36.suppl_A.191"},{"key":"e_1_3_2_13_2","first-page":"717","article-title":"Meta-analysis: a single daily dose of aminoglycosides is as effective as multiple daily dosing in immunocompetent adults.","volume":"124","author":"Hatala R.","year":"1996","unstructured":"Hatala R. Dinh T. Cook D. J. Meta-analysis: a single daily dose of aminoglycosides is as effective as multiple daily dosing in immunocompetent adults. Intern. Med. 124 1996 717 725","journal-title":"Intern. Med."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(88)92121-6","article-title":"Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for the treatment of serious bacterial infections.","author":"Hoepelman I. M.","year":"1988","unstructured":"Hoepelman I. M. Rozenberg-Askra M. Verhoef J. Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for the treatment of serious bacterial infections. Lancet ii 1988 1305 1309","journal-title":"Lancet"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Huizinga W. K. I. B. L. Warren L. W. Baker et al. 1995. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J. Antimicrob. Chemother. 36 (Suppl. A) : 179\u2013190.","DOI":"10.1093\/jac\/36.suppl_A.179"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00003088-199325060-00002","article-title":"Aminoglycoside dosage regimens. Is once a day enough?","volume":"25","author":"Hustinx W. N. M.","year":"1993","unstructured":"Hustinx W. N. M. Hoepelman I. M. Aminoglycoside dosage regimens. Is once a day enough? Clin. Pharmacokinet. 25 1993 427 432","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-198510000-00009"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0002-9343(96)80074-X","article-title":"Comparison of once-daily versus pharmacokinetic dosing of aminoglycoside in elderly patients.","volume":"101","author":"Koo J.","year":"1996","unstructured":"Koo J. Tight R. Rajkumar V. Hawa Z. Comparison of once-daily versus pharmacokinetic dosing of aminoglycoside in elderly patients. Am. J. Med. 101 1996 177 183","journal-title":"Am. J. Med."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1128\/AAC.36.7.1437","article-title":"Pharmacokinetics of meropenem and its metabolite in young and healthy men.","volume":"36","author":"Ljundberg B.","year":"1992","unstructured":"Ljundberg B. Nilsson-Ehle I. Pharmacokinetics of meropenem and its metabolite in young and healthy men. Antimicrob. Agents Chemother. 36 1992 1437 1440","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/jac\/31.6.939","article-title":"Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections.","volume":"31","author":"Maller R.","year":"1993","unstructured":"Maller R. Ahrne H. Holmen C. Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. J. Antimicrob. Chemother. 31 1993 939 948","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2165\/00003495-199652030-00003","article-title":"Aminoglycoside administration as a single daily dose: an improvement to current practice or a repeat of previous errors?","volume":"52","author":"Marra F.","year":"1996","unstructured":"Marra F. Partovi N. Jewssen P. Aminoglycoside administration as a single daily dose: an improvement to current practice or a repeat of previous errors? Drugs 52 1996 344 370","journal-title":"Drugs"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199528040-00002","article-title":"Meropenem clinical pharmacokinetics.","volume":"28","author":"Mouton J. W.","year":"1995","unstructured":"Mouton J. W. van den Anker J. N. Meropenem clinical pharmacokinetics. Clin. Pharmacokinet. 28 1995 275 286","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Mouton Y. J. C. Beuscart and the Meropenem Study Group. 1995. Empirical monotherapy with meropenem in serious bacterial infections. J. Antimicrob. Chemother. 36 (Suppl. A) : 145\u2013156.","DOI":"10.1093\/jac\/36.suppl_A.145"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/jac\/37.4.645","article-title":"A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses.","volume":"37","author":"Munckhof W. J.","year":"1996","unstructured":"Munckhof W. J. Grayson M. L. Turnidge J. D. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J. Antimicrob. Chemother. 37 1996 645 663","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_25_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Approved standard M2-A4 vol. 10 no. 7.\n          1990\n          National Committee for Clinical Laboratory Standards\n          Villanova Pa"},{"key":"e_1_3_2_26_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Approved standard M7-A2 vol. 10 no. 7.\n          1990\n          National Committee for Clinical Laboratory Standards\n          Villanova Pa"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF01964413","article-title":"Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.","volume":"10","author":"Nilsson-Ehle I.","year":"1991","unstructured":"Nilsson-Ehle I. Hutchison M. Haworth S. J. Norrby S. R. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Eur. J. Clin. Microbiol. Infect. Dis. 10 1991 85 88","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Norrby S. R. P. A. Newell K. L. Faulkner and W. Lesky. 1995. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J. Antimicrob. Chemother. 36 (Suppl. A) : 207\u2013223.","DOI":"10.1093\/jac\/36.suppl_A.207"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0140-6736(93)90137-6","article-title":"Once versus thrice daily gentamicin in patients with serious infections.","volume":"341","author":"Prins J. M.","year":"1993","unstructured":"Prins J. M. B\u00fcller H. R. Kuijper E. J. Tange R. A. Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 341 1993 335 339","journal-title":"Lancet"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Romanelli G. P. Cravarezza and the Italian Intramuscular Meropenem Study Group. 1995. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. J. Antimicrob. Chemother. 36 (Suppl. A) : 109\u2013119.","DOI":"10.1093\/jac\/36.suppl_A.109"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","unstructured":"Solberg C. O. and H. Sjursen. 1995. Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime alone or combined with amikacin. J. Antimicrob. Chemother. 36 (Suppl. A) : 157\u2013166.","DOI":"10.1093\/jac\/36.suppl_A.157"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","unstructured":"Topham J. C. L. B. Murgatroyd D. V. Jones U. R. P. Goonetilleke and J. Wright. 1989. Safety evaluation of meropenem in animals: studies on the kidney. J. Antimicrob. Chemother. 24 (Suppl. A) : 287\u2013306.","DOI":"10.1093\/jac\/24.suppl_A.287"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.5.1233","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.5.1233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:58:52Z","timestamp":1645480732000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.42.5.1233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1998,5]]}},"alternative-id":["10.1128\/AAC.42.5.1233"],"URL":"https:\/\/doi.org\/10.1128\/aac.42.5.1233","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,5]]},"assertion":[{"value":"1997-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-03-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}